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Background: Surgical therapy of mid-stage gastric cancer (GC) and other neoplastic conditions requiring 
gastric resection remains at the center of curative outcomes, while epidemiologic changes and multimodality 
treatment options have evolved rapidly. Putative quality metrics for gastrectomy such as R0 rate, total lymph 
node (LN) count or postoperative morbidity may depend partly on changing disease and treatment patterns, 
and deserve evaluation under various practice conditions.
Methods: Data within a U.S.-based single surgical oncologist’s practice over 15 years were prospectively 
recorded and retrospectively analyzed for clinicopathologic factors, operative treatment aspects and 
outcomes. Trends and spectrum changes over three time intervals were analyzed with contingency analysis 
and continuous data comparative statistics.
Results: Of 179 patients undergoing gastric resection, 119 were male and 60 female, with a median age of 
63 years (range, 24–98 years). Resections included 56 total, 56 subtotal/distal, 30 proximal and 37 segmental 
gastrectomies. Diagnoses included 96 GCs, 31 gastroesophageal (GE) junction (GEJ) cancers, 21 GI stromal 
tumors (GISTs), and 31 other conditions. Significant trends from first towards last time interval were observed 
for resection type (16% to 32% proximal, 9% to 30% segmental, P=0.0003), curative intent (76% to 98%, 
P=0.002), diagnosis (5% to 42% GEJ cancer, P<0.0001) and preoperative therapy use (0% to 58%, P<0.0001), 
among others. Intraoperative aspects showed significantly reduced blood loss (median: 500 to 150 mL)  
and transfusion requirements (39% to 4%), and an increased use of minimally invasive techniques over 
time (all at P<0.001). Among patients undergoing curative intent GC resection with LN dissection, total 
LN counts remained steady (mean: 26), while the number of involved LNs decreased (9.0 to 3.7, P=0.0003) 
and the R0 resection rate increased from 74% to 85% (P=0.05). The number of specimens with >15 LNs 
examined increased from 69.0% to 92.5% (P=0.022). At the same time, spleen preservation rate (91% 
overall) and major morbidity (16%) remained unchanged throughout. Postoperative length of stay decreased 
from a median of 12 to 8 days (P<0.0001). 
Conclusions: This experience represents some variable practice patterns within a clinicopathologic 
spectrum of GE diseases. Postoperative or oncologic quality metrics have been sustained or did improve, 
which would support their utility for various practice settings; they compare favorably to other published U.S. 
experiences during the same time period.
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Introduction
Gastric cancer (GC) remains a formidable health care 
challenge worldwide due to some settings of high incidence 
and mortality, and because of the complexity of specific 
treatment options required for best care. In the U.S., 
the incidence of gastric adenocarcinoma (GAC) has 
continuously declined, while that of adenocarcinomas of 
the esophagus and gastroesophageal junction (GEJ) has 
not followed this trend (1). For either process, long-term 
survival remains poor despite recent improvements, as 
many patients afflicted are still diagnosed with advanced-
stage disease, and as available multimodal treatments 
are still limited in efficacy (2). Gastrointestinal stromal 
tumors (GISTs) represent a different clinical spectrum of 
malignant behavior that is being increasingly recognized (3). 
For all these conditions, surgical therapy in form of either 
gastric or gastroesophageal resection remains at the center 
of curative outcomes for mid-stage disease. Due to the 
relatively low prevalence of GC in the U.S., most surgeons 
tend to encounter these disease entities rarely, and specialty 
expertise remains sparse (4). In addition, greater comorbidity 
and inferior survival outcomes have been observed in this 
setting compared to Asian results (5). Characteristic for 
the U.S. system is that reported findings and outcomes 
differ at times widely between single, large centers of 
excellence, smaller case numbers in tertiary care settings, 
and population-based data (6-9). Accordingly, a link between 
high-volume gastrectomy setting and superior outcomes has 
been identified for operative mortality and for long-term 
survival, although low-volume settings do not preclude high 
quality treatment results per se, and therefore volume cannot 
be considered a goal but at best a surrogate for therapeutic 
quality (10,11). More recently, the Centers for Medicare 
and Medicaid Services’ (CMS) Hospital Compare star 
rating system, based on self-reported hospital performance 
regarding clinical outcomes, patient experience, care 
effectiveness, care timeliness, and efficient use of medical 
imaging, has been associated with outcomes including 
readmissions and length of stay (LOS), independent from 
hospital volume (12); however, specific therapeutic metrics 
that can be used as practice standards are not represented. 
How then should standards for surgical GC care that carry 
more universal validity be set, and how should adherence to 
therapeutic quality standards be measured?
In this context the value of care, primarily to patients 
but also to payers and other stakeholders, carries great 
significance. Aside from the growing mandate to limit costs 
of care, actual quality aspects of cancer care have become 
increasingly recognized as being important. However, how 
to measure relevant quality aspects remains a formidable 
challenge in general, and this extends specifically into 
operative cancer management such as for GC. Currently, 
quality metrics as mandated by payers or regulatory agencies 
often address process-linked, “measurable” aspects that 
arguably carry little meaning for true “quality” of care (13). 
Day-to-day healthcare may generate more emphasis on 
whether an operation has been done, compared to how it 
has been planned, performed or supported. Aspects such as 
appropriateness of the indication in general, or the timing 
of operative care within the multidisciplinary therapy 
spectrum are less commonly traced. On the other hand, 
general surgical and oncologic principles that impact upon 
quality of care are widely accepted, including quality of 
staging, proper multimodality treatment planning, defining 
therapeutic intent, completeness of resection (including 
margin-negativity rate), minimizing treatment-associated 
risks (through spleen preservation, avoidance of blood 
transfusions), and steps for optimizing recovery and early 
outcomes as reflected by low postoperative complication 
rates and limited length of hospital stay (14,15). The current 
study was undertaken to examine clinical patterns of GC 
treatment within a gastrectomy experience in an academic 
surgical oncology practice longitudinally, and to evaluate 
potential metrics for therapeutic quality components as 
outlined within the identified spectrum of care.
Methods
The analysis examined consecutive patients undergoing 
gastric resection in a U.S.-based single surgical oncologist’s 
practice experience over 15 years, with the intent to identify 
clinical spectrum changes or trends of potential significance, 
and to assess parameters with possible relevance to surgical 
quality performance within this clinical spectrum. Data 
on patient demographics, clinicopathologic factors, 
operative treatment aspects and postoperative outcomes 
were prospectively recorded. The American Society of 
Anesthesiologists’ (ASA) classification was used for operative 
risk assignments. Underlying diagnoses were categorized 
based on histopathologic analyses of the resected specimens. 
Most patients had malignant or premalignant neoplastic 
conditions; however, gastrectomies performed for non-
neoplastic processes remained included to support complete 
evaluation of non-cancer-specific quality metrics. Malignant 
tumors in this series originated from or involved gastric 
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mural components between the GEJ and the pylorus; 
esophageal adenocarcinomas with an epicenter above the 
GEJ were excluded. For characterization of GEJ cancers, 
the classification of Siewert was utilized. TNM staging was 
performed for adenocarcinomas of the stomach or GEJ 
using 7th edition AJCC criteria. 
Intraoperative therapeutic components, postoperative 
findings and outcomes were examined based on their 
putative relationship to surgical quality performance. These 
parameters included intraoperative blood loss, transfusions, 
completeness of resection (R category), spleen preservation, 
lymph node (LN) counts, postoperative morbidity and LOS. 
Transfusions included intra- and post-operative packed red 
blood cell (PRBC) transfusions administered irrespective of 
preoperative blood counts or intraoperative blood loss. LN 
counts were reviewed for total LNs examined, number of 
positive LNs identified histopathologically, and number of 
negative LNs; LN count analyses were restricted to patients 
with an indication for extended LN dissection (ELND), 
thus excluding patients with GISTs, benign diagnoses or 
merely noncurative gastrectomy for palliation of GC-related 
symptoms. For patients with GAC undergoing curative-
intent resection, the percent of cases with at least 15 or more 
LNs examined was assessed, based on common staging 
conventions; in addition, cut-points of >15 LNs (i.e., 16 
or more), as formulated within the AJCC staging criteria, 
and of 20 or more total LNs were examined. Postoperative 
complications were charted prospectively and graded 
according to the classification of Clavien-Dindo; grade 1 and 
2 events were defined as minor, grade 3 through 5 events 
as major morbidity. In case of multiple complications, the 
highest-grade event was chosen. Any complications or lethal 
events reflect occurrences during the longer time interval of 
either in-hospital stay or 30 days postoperatively.
Clinical trends and spectrum changes were examined 
through dividing the cohort by three equal time intervals, 
each encompassing 5 years. Data are presented via 
descriptive statistics. Interval comparisons were made 
through contingency chi square analysis for categorical 
data, and analysis of variance (ANOVA) or Kruskal-Wallis 
tests for continuous data as appropriate based on data 
distribution. Significance of differences was accepted at 
P≤0.05. The StatView (SAS, Cary, NC, USA) software 
package was chosen for statistical analysis.
Results
The cohort for this analysis consisted of 179 patients who 
had undergone gastric resection. Of these, 119 were male and 
60 female, with a median age of 63 years (range, 24–98 years). 
Diagnoses included 96 GACs, 31 GE junction cancers, 
21 GISTs, and 31 other conditions requiring some form 
of gastrectomy. Among the latter group, there were three 
neuroendocrine tumors, two soft tissue sarcomas, two nerve 
sheath tumors, three other benign neoplasms, five cases of 
isolated gastric involvement of other malignant neoplasms, 
and 16 cases with non-neoplastic gastric conditions. When 
evaluating trends over three consecutive time intervals, 
patient gender and age did not show obvious differences over 
time, while the distribution of diagnoses did: GEJ cancers 
became more prevalent over time, while the number of GACs 
operated upon decreased significantly (Table 1). Preoperative 
therapy, either in form of chemotherapy or chemoradiation, 
was given in 22% of patients overall, trending from 0% to 
58% over time (P<0.0001).
Operative risk categories remained stable over time, with 
60% of patients carrying ASA class 3, 31% class 2, 7% class 
4 and 2% class 1 assignments. Five percent of gastrectomies 
were emergency procedures, while 95% were elective; 13% 
of resections in the first period were emergent, compared 
to 3% in the second and none in the last period (P=0.006). 
The preoperative intent among patients with a malignant 
or neoplastic condition (n=163) shifted over time as well, 
with an increase in the subset of patients operated upon with 
curative intent from 76% initially to 98%, and a decrease 
in palliation intent from 33% to 9% (Table 1). A diagnostic 
laparoscopy prior to definitive resection was performed 
in 63% of all patients (67% of cancer patients, and 74% 
of cancer patients with curative intent, P<0.0001), usually 
during the same procedure. There were only 11 minimally 
invasive surgical (MIS) procedures, all but one in the most 
recent period. An abdominal incision only was utilized for 
95% of cases, compared to a thoracoabdominal incision 
in 5%. Resections included 56 total, 30 subtotal, 26 distal 
and 37 segmental gastrectomies, in addition to 30 proximal 
gastrectomies (or esophagogastrectomies for Siewert type 
1/2 GEJ cancers). Additional operative components were 
ELND in 72%, splenectomy in 9%, multivisceral resection 
in 24%, and feeding jejunostomy tube placement in 65% 
of cases. Reconstructive techniques included an esophageal 
anastomosis in 48%, and specifically employed jejunal Roux-Y 
reconstruction (n=106, 59%), primary esophagogastrostomy 
with or without gastric pullup (n=20, 11%), Merendino small 
bowel interposition (n=6, 3%), Billroth-2 gastrojejunostomy 
(n=16, 9%) or primary gastric closure (n=31, 17%). Total 
operative time (mean: 5.4 h, P=0.004) and intravenous fluid 
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Table 1 Demographic, clinical and therapeutic parameters, by time period
Variable Total cohort Period 1 Period 2 Period 3 P value
Total patients 179 56 66 57 N/A
Gender, n [%] NS 
Male 119 [66] 37 [66] 42 [64] 40 [70]
Female 60 [34] 19 [34] 24 [36] 17 [30]
Age, median [range], years 63 [24–98] 62 [34–98] 62 [24–94] 65 [27–85] NS
Diagnosis, n [%] <0.0001
GAC 96 [54] 39 [70] 42 [64] 15 [26]
GEJ cancer 31 [17] 4 [7] 3 [5] 24 [42]
GIST 21 [12] 3 [5] 9 [14] 9 [16]
others 31 [17] 10 [18] 12 [18] 9 [16]
Preoperative therapy, n [%] 39 [22] 0 [0] 6 [9] 33 [58] <0.0001
Resection intent*, n [%]
Curative 144 [88] 37 [76] 54 [90] 53 [98] 0.002
Palliative 42 [26] 16 [33] 21 [35] 5 [9] 0.003
Gastrectomy type, n [%] 0.0003
Total 56 [31] 20 [36] 22 [33] 14 [25]
Subtotal, incl. distal, n [%] 56 [31] 22 [39] 26 [39] 8 [14]
Proximal 30 [17] 9 [16] 3 [5] 18 [32]
Segmental 37 [21] 5 [9] 15 [23] 17 [30]
Esophageal anastomosis, n [%] 86 [48] 28 [50] 26 [39] 32 [56] NS
ELND performed, n [%] 129 [72] 42 [75] 47 [71] 40 [70] NS
Laparoscopy performed, n [%] 112 [63] 34 [61] 35 [53] 43 [75] 0.036
MIS resection, n [%] 11 [6] 0 [0] 1 [2] 10 [18] <0.0001
Multivisceral resection, n [%] 43 [24] 15 [27] 21 [32] 7 [12] 0.034
T category (patients with AC only), n [%] 0.042
T0 9 [7] 0 [0] 2 [5] 7 [18]
T1–2 57 [46] 20 [48] 26 [60] 11 [28]
T3 44 [35] 17 [40] 11 [26] 16 [41]
T4 14 [11] 5 [12] 4 [9] 5 [13]
Positive LNs, mean n 5.5 9.0 4.2 3.7 0.0003
Stage group (patients with AC only), n [%] 0.0007
0–2 64 [52] 15 [36] 27 [63] 22 [56]
3 33 [27] 9 [21] 10 [23] 14 [36]
4 27 [22] 18 [43] 6 [14] 3 [8]
Numbers reflect patient n, with percentages in parentheses (% within columns for subcategories, or % of patients within time period; 
percentages are rounded) unless listed otherwise. *, based on 163 patients with malignancy or benign neoplasms; sums of resection 
intent percentages do not match 100 due to overlap of curative and palliation intent combined. GAC, gastric adenocarcinoma; GEJ, 
gastroesophageal junction; GIST, gastrointestinal stromal tumor; ELND, extended lymph node dissection; MIS, minimally invasive surgical 
procedure; LNs, lymph nodes; N/A, not applicable; NS, not significant; AC, adenocarcinoma.
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administration (mean: 5,160 mL, P=0.001) showed differences 
but no trends between time periods.
Characteristics for operative and pathologic variables 
throughout the time periods are also listed in Table 1. No 
differences were seen for esophageal anastomosis or ELND 
frequencies. Time-dependent differences but no trends 
between the three time periods were observed for use of 
laparoscopy and multivisceral resections. Significant differences 
with directional trends between time periods were noticed 
for preoperative therapy, gastrectomy type, MIS resections, 
the T0 staging category for adenocarcinomas, positive LN 
number, and adenocarcinoma stage groups 3 (increase from 
20% to 37%) and 4 (decrease from 44% to 8%); in addition, 
reconstructive techniques differed (P=0.0009), with trends for 
Roux-Y (71% to 40%), small bowel interposition (2% to 5%) 
and primary closure (7% to 26%).
Additional variables as possible metrics for quality of care are 
listed in Table 2. Significant trends over time were detected for 
intraoperative blood loss, transfusion rates, and R categories. 
The overall R0 rate in 149 patients with malignancy was 81%, 
while among 112 cancer patients with curative resection intent 
and no palliative indication, a R0 resection was performed 
in 104 (93%). In 37 patients with malignancy and palliation 
needs, a R0 resection was still achieved in 43% (R1: 16%, R2: 
41%). The spleen preservation rate change from 88% to 95% 
did not reach significance. While total LN count differences 
were also not significant (overall mean: 26.2), number of 
negative LNs and the percentage of reports with at least 15 
or more than 15 LNs showed obvious trends. Postoperative 
morbidity consisted of minor morbidity in 19% and major 
morbidity in 16% of cases, the latter including eight deaths 
(4%); lethal events occurred in 3.3% of cancer patients without 
palliation needs, in 4.8% of palliative cancer resections, and in 
15.4% of patients with “benign” (non-neoplastic) diagnoses. 
Table 2 Therapeutic and outcome parameters with potential quality implications
Variable Total cohort Period 1 Period 2 Period 3 P value
Total patients 179 56 66 57 N/A
Estimated blood loss, mean [SD], mL 363 [336] 571 [338] 365 [356] 221 [223] <0.0001
Blood transfusion (mean PRBC units per patient) 0.52 0.71 0.82 0.04 0.003
Blood transfusion, n [%] 41 [23] 22 [39] 19 [29] 2 [4] <0.0001
Spleen preservation, n [%] 163 [91] 49 [88] 60 [91] 54 [95] NS
Completeness of resection 0.017
R0 120 [81] 31 [72] 47 [82] 42 [86]
R1 13 [9] 2 [5] 5 [9] 6 [12]
R2 16 [11] 10 [23] 5 [9] 1 [2]
Total LN count 26.2 24.8 26.1 27.7 NS
Negative LN count 20.7 15.8 21.9 24.0 0.024
15+ LNs for curative intent ELND, % of patients 80.6 73.8 74.5 95.0 0.022
>15 LNs for curative intent ELND, % of patients 77.5 69.0 72.3 92.5 0.022
20+ LNs for curative intent ELND, % of patients 69.8 61.9 66.0 82.5 NS
Postoperative morbidity NS
None 117 [65] 33 [59] 46 [70] 38 [67]
Minor 34 [19] 10 [18] 12 [18] 12 [21]
Major 28 [16] 13 [23] 8 [12] 7 [12]
Length of stay, median [range], days 9 [3–113] 12 [5–113] 8 [4–45] 8 [3–66] <0.0001
Numbers reflect patient n, with percentages in parentheses (% within columns for subcategories, or % of patients within time period; 
percentages are rounded) unless listed otherwise. PRBC, packed red blood cells; ELND, extended lymph node dissection; SD, standard 
deviation; N/A, not applicable; NS, not significant. 
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Decreasing trends in major morbidity or lethal events failed to 
reach significance. Finally, the postoperative LOS decreased 
from a median of 12 to 8 days; it also demonstrated obvious 
differences based on complexity of resection and postoperative 
morbidity (Figure 1). Other variables with impact on longer 
LOS included emergency resection, splenectomy, transfusion 
and reconstruction in form of esophagogastric anastomoses or 
interposition techniques (all at P<0.001).
Discussion
What represents quality in a complex clinical context, 
and how should it be measured? It is not by chance 
that metrics currently in place to assess surgical quality 
performance are typically reflective of process-related 
aspects, such as preoperative antibiotic administration, 
postoperative urinary catheter removal or initiation of 
thromboembolic prophylaxis (13). While these aspects 
undoubtedly carry some general importance, they are 
likely falling short to address domains that carry greater 
relevance to direct disease-specific patient benefits, 
appropriateness of care, and achieving best meaningful 
long-term outcomes. Approaching quality as an essential 
element to optimizing overall value would seem to benefit 
from the understanding that patient beneficence has to 
be the priority, and metrics considered most appropriate 
would need to reflect this aspect comprehensively and 
adequately representing the breadth of care spectrum (13). 
Equally, incentives or penalties to promote “quality” of care 
would need to recognize the complexity of components 
surrounding patient benefits, rather than relying on few 
selected and possibly incomplete metrics. Creating value 
for other stakeholders, or minimizing costs to payers and 
society are additional important practice components in 
the effort to optimize quality and value of care. How, then, 
should metrics be selected that are therapeutically relevant 
and reflect quality of upper GI cancer care delivered 
appropriately?
In this series, an effort was made to analyze components 
of operative and postoperative care as well as early outcomes 
for patient undergoing gastrectomy in a U.S.-based 
oncology practice setting. The data show a considerable 
variability of clinical indications and therapies, even in 
this relatively short time span of 15 years. While some of 
the changes or trends observed may well represent special 
practice referral patterns that are not entirely reflective 
of general trends, some changes nevertheless are sensible 
given the evolution of GC care in the past two decades: 
there is a significant shift away from distal GC to more GEJ 
cancers, and there are currently more noninvasive palliation 
options not requiring operative intervention any longer (14); 
additionally, there is a shift towards preoperative 
chemotherapy or chemoradiation for mid-stage gastric and 
GEJ cancers that qualify for curative intent treatment (16). 
Finally, there are changes in GIST resections consistent 
with an increasing recognition of GISTs representing a 
spectrum of neoplasms with unique biologic behavior and 
treatment response for which resective indications have 
become more refined (3,17). Under these circumstances, it 
appears to be a worthwhile exercise to analyze how possible 
quality metrics for oncologic and surgical care have fared, 
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Figure 1 Postoperative length of stay (LOS). (A) LOS by time 
period; (B) LOS by gastrectomy type; (C) LOS by morbidity grade. 
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and whether any specific trends over time can be elucidated.
The data reveal time-dependent variations in diagnosis, 
a relative increase in curative-intent resections, more 
proximal resections, more MIS procedures, a significantly 
grown proportion of patients receiving preoperative 
therapy, and, likely related to this, fewer positive LNs and 
a shift towards earlier stages. Importantly, the operative 
complexity appears to have remained unchanged, based on 
consistent multivisceral resection needs, lymphadenectomy 
indications or esophageal anastomoses performed. Given 
these clinical shifts, operative blood loss and blood 
transfusion needs seemed to have followed a reducing 
trend. The higher rate of R0 resections is likely impacted 
by reduced palliation needs and utilization of preoperative 
therapies, but may also speak favorably in light of an 
increased number of proximal resections. In addition, R1 
results are also influenced by intraoperative peritoneal 
washing cytology results that were routinely obtained in 
the first time period, and selectively but in every case of 
obvious or suspected serosal involvement thereafter. In 
contrast, R2 resections resulted almost exclusively from 
settings of palliation needs. In addition to care aspects 
where changes have been observed over time, more telling 
insight can perhaps be retrieved where consistent results 
rather than “trends” have been identified; these included 
total LN counts, spleen preservation rate or postoperative 
morbidity. For the former two, a consistency of practice 
and the observed results have been intended due to a 
perceived oncologic importance (18-20). Total or negative 
LN counts have been associated with superior survival 
results, although a direct causation remains unproven in 
the era of multimodality treatment options for GC (21-23). 
A slight increase in negative LN counts over time likely 
reflects preoperative therapy impact more than changes in 
dissection extent or pathologic examination. Overall, the 
number of LN obtained and the ability to properly stage 
patients based on a minimum LN number seem to compare 
favorably with other published contemporary results from 
North American centers: the median LN count in a recent 
National Cancer Database report has been 2 (24), while 
in academic centers represented in the US Gastric Cancer 
Collaborative it was 16 (25). The percentage of gastrectomy 
specimens with 15 or more LNs examined has been 
reported as 42% in the California Cancer Registry (26) and 
as 51% in the before mentioned academic collaborative (25), 
compared to 81% overall in the current series, and 95% for 
the last time period. The trend in reduced LOS is reflective 
of shorter hospital durations for other surgical oncologic 
procedures, not just gastroesophageal resections (27,28); 
this is noteworthy, given a high prevalence of elderly 
patients and a constant morbidity rate, which both impact 
on the length of hospitalization (29). Spleen preservation 
rate, blood loss estimates and transfusion requirements in 
this series resemble closely those reported for curative R0 
resections by Squires et al. based on combined academic 
institution data (30). 
This series primarily compiles operative and early 
outcome aspects, and cannot and does not intend to 
make general claims on other aspects relevant to quality 
of care since it represents a single surgeon’s experience. 
Some parameters are not reported since they were either 
not prospectively or completely recorded, such as details 
of multidisciplinary treatment planning, costs of care or 
patient-reported aspects such as quality of life. Others 
remain challenging to define, e.g., appropriateness of care, 
especially gastrectomy indications outside the intention to 
cure a malignant process. For many potential therapeutic 
quality metrics, a key challenge is that clinical significance 
and impact remain arguable, as direct causative links to 
outcome differences are frequently not established. An 
example for this is the preservation of a duodenal passage 
after gastrectomy that while sensibly desirable has not been 
shown to lead to significant measurable patient benefits (31). 
The appropriateness of some metrics may also change, 
such as total LN counts for resected rectal cancer that are 
difficult to associate to better overall survival in light of 
preoperative chemoradiation (32); this particular aspect 
may carry relevance to GC in the setting of preoperative 
chemoradiation or perioperative chemotherapy, too.
How, then, should the discussion on quality metrics for 
surgical GC care be directed? A process that establishes 
consensus on which metrics are worthy of more universal 
adoption based on creating patient benefit and generating 
value to other stakeholders appears desirable. Efforts 
to develop enhanced postoperative recovery pathways 
can serve as example for such aspects of perioperative 
care, although their benefits over standard practice will 
still remain debatable unless impacted outcomes are 
measured and found to be benefited (15,33). Adherence to 
standardized practice pathways is thus not proposed to be 
used as surrogate for quality care, but rather measurement 
of relevant outcomes for patient-centered care should 
drive this process (34). An example for selection of relevant 
metrics and establishing benchmarks is the National 
Quality Forum colon cancer project (35); a similar forum, 
supported or endorsed by specialty professional societies 
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and other stakeholders could be created for GC care. In 
addition to selecting therapeutic and outcome metrics, it 
could recommend which patient-reported parameters are 
to be chosen, since these are rarely studied prospectively 
and tend to vary widely (36,37). Although some initial 
efforts to nationally standardize quality metrics for cancer 
care tend to select parameters at what some would consider 
minimum-requirement thresholds, a beneficial clinical 
aspect has become traceable (35,38,39). 
Presenting the results of this study is intended to make 
a contribution to the discussion on how some therapeutic 
and outcome parameters can be applied within variable 
practice conditions, and on which metrics can be considered 
useful for setting internal quality standards and derived 
benchmarks in the future. Although surgeons may be 
exposed to a variety of clinical practice needs, it appears 
from this experience that the proposed metrics as applied 
can serve as informative, reliable and consistent parameters 
to inform on quality-related aspects of surgical GC care and 
other conditions requiring gastrectomy.
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